Imvax

PHILADELPHIA, PA — Imvax, Inc, recently closed a $29 million financing round from existing investors. This marks the latest milestone in the company’s fundraising efforts, which have totaled $86 million …

PHILADELPHIA, PA — Imvax, Inc. has announced the completion of enrollment in its Phase 2b clinical trial of IGV-001, a novel treatment for newly diagnosed glioblastoma (ndGBM). The trial, which …